Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis

AIMS: A new formulation, low dose microencapsulated aspirin, permits slow absorption of aspirin and presystemic acetylation of platelet cyclo-oxygenase within the portal circulation, potentially avoiding deleterious effects on gastric and systemic prostaglandin synthesis. The objective of this study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Brown, Nigel, May, Jane A, Wilcox, Robert G, Allan, Linda M, Wilson, Adrian M, Kiff, Peter S, Heptinstall, Stan
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 1999
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2014875/
https://ncbi.nlm.nih.gov/pubmed/10383561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00947.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars